Marksans Pharma said it has received an establishment inspection report (EIR) from the US health regulator for company’s manufacturing facility in the US.
In a regulatory filing, the company announced “receipt of the EIR from US Food and Drug Administration (US FDA) in respect of inspection of company’s manufacturing facility Time-Cap Laboratories located at Farmingdale, New York, USA carried out from December 5, 2019 to December 18, 2019”.